(WEAV) Weave Communications - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 479m USD | Total Return: -35.8% in 12m

Communication Software, Payment Processing, Patient Engagement, Practice Analytics

Total Rating 32

Safety 28

Buy Signal -0.25

Health Information Services
Industry Rotation: +9.7

Market Cap: 479M
Avg Turnover: 5.72M

Risk 3d forecast

Volatility57.0%

VaR 5^th Pctl9.13%

VaR vs Median-3.28%

Reward TTM

Sharpe Ratio-0.65

Rel. Str. IBD18.2

Rel. Str. Peer Group49.6

Character TTM

Beta1.578

Beta Downside1.550

Hurst Exponent0.398

Drawdowns 3y

Max DD74.94%

CAGR/Max DD-0.10

CAGR/Mean DD-0.24

EPS (Earnings per Share)

Last SUE: 0.19
Qual. Beats: 0

Revenue

Rev. CAGR: 18.71%
Rev. Trend: 99.9%

Last SUE: 0.65
Qual. Beats: 0

Warnings

Interest Coverage Ratio -14.8 is critical

Beneish M-Score -1.15 > -1.5 - likely earnings manipulation

Altman Z'' -8.22 < 1.0 - financial distress zone

Choppy

Tailwinds

Confidence

Description: WEAV Weave Communications

Weave Communications, Inc. (WEAV) provides an integrated, AI-driven software-as-a-service (SaaS) platform designed for small and medium-sized healthcare practices. The platform consolidates patient communication, clinical administration, and financial processing into a single interface. Key functionalities include automated scheduling, digital intake forms, insurance verification, and a comprehensive payment processing solution.

The company operates within the specialized vertical SaaS sector, where software is tailored to the specific regulatory and workflow requirements of industries like dentistry, optometry, and veterinary medicine. This business model typically benefits from high switching costs and deep integration with existing electronic health record (EHR) systems. By automating front-office tasks such as missed-call replies and review solicitation, the platform aims to reduce administrative overhead for local clinics.

For a detailed breakdown of the companys valuation metrics and historical growth, consider reviewing the latest data on ValueRay.

Founded in 2008 and headquartered in Lehi, Utah, Weave also offers enterprise-level tools for multi-location groups and dental service organizations. Its suite includes practice analytics for monitoring patient retention and treatment acceptance rates, alongside mobile tools that allow practitioners to manage patient interactions remotely.

Headlines to Watch Out For

Expansion into multi-location enterprise healthcare practices drives higher average revenue per user
Adoption of integrated payment processing solutions accelerates non-subscription transaction revenue growth
High customer acquisition costs relative to lifetime value impacts path to profitability
Integration of AI automation tools reduces churn by increasing practice workflow efficiency
Consolidation among small dental and medical practices creates client retention risk

Piotroski VR-10 (Strict) 4.5

Net Income: -25.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -11.57 > 1.0
NWC/Revenue: 7.88% < 20% (prev 21.17%; Δ -13.29% < -1%)
CFO/TA 0.06 > 3% & CFO 12.1m > Net Income -25.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.24 > 1.5 & < 3
Outstanding Shares: last quarter (78.6m) vs 12m ago 6.46% < -2%
Gross Margin: 72.28% > 18% (prev 0.72%; Δ 7.16k% > 0.5%)
Asset Turnover: 126.7% > 50% (prev 113.1%; Δ 13.62% > 0%)
Interest Coverage Ratio: -14.76 > 6 (EBITDA TTM -7.97m / Interest Expense TTM 1.67m)

Altman Z'' -8.22

A: 0.10 (Total Current Assets 100.7m - Total Current Liabilities 81.1m) / Total Assets 204.3m
B: -1.59 (Retained Earnings -324.8m / Total Assets 204.3m)
C: -0.13 (EBIT TTM -24.7m / Avg Total Assets 196.3m)
D: -2.69 (Book Value of Equity -325.2m / Total Liabilities 121.0m)
Altman-Z'' = -8.22 = D

Beneish M -1.15

DSRI: 1.27 (Receivables 4.64m/3.13m, Revenue 248.7m/212.9m)
GMI: 0.99 (GM 72.28% / 71.77%)
AQI: 3.91 (AQ_t 0.25 / AQ_t-1 0.06)
SGI: 1.17 (Revenue 248.7m / 212.9m)
TATA: -0.18 (NI -25.0m - CFO 12.1m) / TA 204.3m)
Beneish M = -1.15 (Cap -4..+1) = D

What is the price of WEAV shares?

As of June 01, 2026, the stock is trading at USD 6.02 with a total of 957,701 shares traded.
Over the past week, the price has changed by +7.31%, over one month by +22.61%, over three months by +12.95% and over the past year by -35.82%.

Is WEAV a buy, sell or hold?

Weave Communications has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy WEAV.

StrongBuy: 4
Buy: 1
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the WEAV price?

Analysts Target Price	8.8	45.3%

Weave Communications (WEAV) - Fundamental Data Overview as of 31 May 2026

Market Cap USD = 479.0m (479.0m USD * 1.0 USD.USD)
P/S = 1.9258
P/B = 5.7517
Revenue TTM = 248.7m USD
EBIT TTM = -24.7m USD
EBITDA TTM = -7.97m USD
Long Term Debt = 39.7m USD (estimated: total debt 51.3m - short term 11.6m)
Short Term Debt = 11.6m USD (from shortTermDebt, last quarter)
Debt = 51.3m USD (from shortLongTermDebtTotal, last quarter) (leases 51.3m already included)
Net Debt = -21.4m USD (calculated: Debt 51.3m - CCE 72.7m)
Enterprise Value = 457.6m USD (479.0m + Debt 51.3m - CCE 72.7m)
Interest Coverage Ratio = -14.76 (Ebit TTM -24.7m / Interest Expense TTM 1.67m)
EV/FCF = 47.72x (Enterprise Value 457.6m / FCF TTM 9.59m)
FCF Yield = 2.10% (FCF TTM 9.59m / Enterprise Value 457.6m)
FCF Margin = 3.86% (FCF TTM 9.59m / Revenue TTM 248.7m)
Net Margin = -10.05% (Net Income TTM -25.0m / Revenue TTM 248.7m)
Gross Margin = 72.28% ((Revenue TTM 248.7m - Cost of Revenue TTM 68.9m) / Revenue TTM)
Gross Margin QoQ = 72.38% (prev 72.66%)
Tobins Q-Ratio = 2.24 (Enterprise Value 457.6m / Total Assets 204.3m)
Interest Expense / Debt = 3.26% (Interest Expense 1.67m / Debt 51.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -19.5m (EBIT -24.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.24 (Total Current Assets 100.7m / Total Current Liabilities 81.1m)
Debt / Equity = 0.62 (Debt 51.3m / totalStockholderEquity, last quarter 83.3m)
Debt / EBITDA = 2.69 (negative EBITDA) (Net Debt -21.4m / EBITDA -7.97m)
Debt / FCF = -2.23 (Net Debt -21.4m / FCF TTM 9.59m)
Total Stockholder Equity = 80.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.73% (Net Income -25.0m / Total Assets 204.3m)
RoE = -6.16% (Net Income TTM -25.0m / Total Stockholder Equity 405.6m)
RoCE = -5.54% (EBIT -24.7m / Capital Employed (Equity 405.6m + L.T.Debt 39.7m))
RoIC = -14.47% (negative operating profit) (NOPAT -19.5m / Invested Capital 134.8m)
WACC = 10.66% (E(479.0m)/V(530.3m) * Re(11.53%) + D(51.3m)/V(530.3m) * Rd(3.26%) * (1-Tc(0.21)))
Discount Rate = 11.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.21 | Cagr: 6.89%
[DCF] Terminal Value 64.98% ; FCFF base≈18.0m ; Y1≈15.8m ; Y5≈12.8m
[DCF] Fair Price = 2.14 (EV 148.5m - Net Debt -21.4m = Equity 169.9m / Shares 79.6m; r=10.66% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: 99.91 | Revenue CAGR: 18.71% | SUE: 0.65 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.04 | Chg30d=N/A | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=+5.88% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=0.17 | Chg30d=+17.54% | Revisions=+43% | GrowthEPS=+109.4% | GrowthRev=+15.9%
EPS next Year (2027-12-31): EPS=0.23 | Chg30d=+13.25% | Revisions=+43% | GrowthEPS=+40.3% | GrowthRev=+13.9%
[Analyst] Revisions Ratio: +43%